INDIANAPOLIS--The federal government is stopping the distribution of a COVID-19 antibody treatment by Eli Lilly on its own because of an increase in coronavirus variants across the U.S.
Bamlanivimab can still be used with etesevimab, which is another monoclonal antibody treatment developed by Eli Lilly. The Food and Drug Administration says the two Eli Lilly treatments seem to work against the variants as a combination, but not as standalone treatments.
Operation Warp Speed invested in the treatment throughout its development. In December, the US government spent $812.5 million to buy 650,000 additional doses of bamlanivimab.
The government has sent out nearly 800,000 doses of bamlanivimab as of March 2. The updated guidance says that if health care providers want to use their existing supply of bamlanivimab, they can.
- Pence: Trump Owes it to the American People to Debate
- FOUND: Momo the Monkey on the Loose: Indianapolis’ East Side on High Alert
- Pacers GM: Contract Extension Talks with Buddy Hield Are “At a Halt” But That Doesn’t Mean They’re Done
- NWS: Expect a Rainy Wednesday Across Indiana
- Murder Suspect Kevin Mason Captured
The Dangers of Brown Friday & How You Can Prepare for the Worst
Small Plane Crashes Near Shelbyville Airport, Two People Dead
Feds, Rush County Sheriff Search Home In Valerie Tindall's Disappearance
Police: Woman Killed, Infant Hurt in Head-On Crash with Semi-Truck
Fishers Marching Band Appears in 2023 Macy's Parade
Indiana State Police K9 Koda Receives Life-Saving Armor
Indianapolis Firefighter Among More than 20 Arrested in Child Solicitation Sting
Big Ten Championship Game's Future in Indianapolis Uncertain After 2024.